MedTrace Logo

Liposomal Bupivacaine After Cesarean Delivery

NCT03907813 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-07-31

No results posted yet for this study

Summary

The aim of this study is to determine if local wound infiltration with liposomal bupivacaine at the time of cesarean delivery can decrease opioid use and provide adequate post-operative pain control.

Conditions

  • Pain, Postoperative
  • Opioid Use

Interventions

DRUG

Exparel

liposomal bupivacaine wound infiltration

OTHER

Saline infiltration

saline wound infiltration

Sponsors & Collaborators

  • Wright State University

    lead OTHER

Principal Investigators

  • Marilyn Kindig, DO · Wright State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-06-30
Completion
2020-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03907813 on ClinicalTrials.gov